Sponsor Pipeline

Ryvu Therapeutics SA Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
3
Recruiting
5
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-07-29 NCT06987058
RVU120 Rollover Study		 Enrolling by invitation only
2026-07-29 NCT06987058
RVU120 Rollover Study		 Enrollment increased: 10 -> 14 participants
Active Trials by Phase
Phase 2
5
Phase 1/2
1
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06191263 Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of… Acute Myeloid Leukemia Recruiting
NCT06397313 RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis Myelofibrosis Recruiting
NCT06534437 MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma… Non-Hodgkin Lymphoma, B-cell Recruiting
NCT06268574 Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML Acute Myeloid Leukemia (AML) Active, Not Recruiting
NCT06987058 RVU120 Rollover Study Advanced Solid Tumors Enrolling by Invitation
Phase 1/2
NCT05052255 RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors Advanced Solid Tumor Active, Not Recruiting
Disease Areas
Leukemia (3) Acute Myeloid Leukemia (AML) (3) Myelodysplastic Syndromes (MDS) (2) Myelofibrosis (1) Non-Hodgkin Lymphoma (1)
Get alerts when Ryvu Therapeutics SA's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free